1 Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor

2 Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological

- 3 Sex.
- 4 Nancy R. Graham^{1,2}, Annalis N. Whitaker^{3,4,5}, Camilla A. Strother^{1,4}, Ashley K. Miles^{1,2}, Dore
- 5 Grier⁶, Benjamin D. McElvany^{1,2}, Emily A. Bruce^{3,5,11}, Matthew E. Poynter^{4,5,7,8,11}, Kristen K.
- 6 Pierce^{1,2,9,11}, Beth D. Kirkpatrick^{1,2,5,9,11}, Renee D. Stapleton^{7,8}, Gary An^{10,11}, Jason W.
- 7 Botten^{1,2,3,4,5,11}, Jessica W. Crothers^{5,9}, Sean A. Diehl^{1,2,4,5,11,*}

8 AFFILIATIONS

- ¹Department of Microbiology and Molecular Genetics, ²Vaccine Testing Center, ³Department of
- 10 Medicine-Immunobiology, ⁴Cellular, Molecular, and Biomedical Sciences Graduate Program,
- ⁵Vermont Center for Immunology and Infectious Disease, ⁶Department of Pathology and
- 12 Laboratory Medicine, ⁷Vermont Lung Center, ⁸Department of Medicine-Pulmonary and Critical
- 13 Care, ⁹Medicine-Infectious Disease, ¹⁰Department of Surgery, ¹¹Translational Global Infectious
- 14 Disease Research Center, Larner College of Medicine University of Vermont, Burlington, VT,
- 15 05405, USA
- 16 *correspondence: <u>sean.diehl@med.uvm.edu</u>

17 ABSTRACT

18 SARS-CoV-2 is the newly emerged virus responsible for the global COVID-19 pandemic. There 19 is an incomplete understanding of the host humoral immune response to SARS-CoV-2 during 20 acute infection. Host factors such as age and sex as well the kinetics and functionality of 21 antibody responses are important factors to consider as vaccine development proceeds. The 22 receptor-binding domain of the CoV spike (RBD-S) protein is important in host cell recognition 23 and infection and antibodies targeting this domain are often neutralizing. In a cross-sectional 24 study of anti-RBD-S antibodies in COVID-19 patients we found equivalent levels in male and 25 female patients and no age-related deficiencies even out to 93 years of age. The anti-RBD-S 26 response was evident as little as 6 days after onset of symptoms and for at least 5 weeks after 27 symptom onset. Anti-RBD-S IgG, IgM, and IgA responses were simultaneously induced within 28 10 days after onset, but isotype-specific kinetics differed such that anti-RBD-S IgG was most 29 sustained over a 5-week period. The kinetics and magnitude of neutralizing antibody formation 30 strongly correlated with that seen for anti-RBD-S antibodies. Our results suggest age- and sex-31 related disparities in COVID-19 fatalities are not explained by anti-RBD-S responses. The multi-32 isotype anti-RBD-S response induced by live virus infection could serve as a potential marker by 33 which to monitor vaccine-induced responses.

- 34 Key words: COVID-19, SARS-CoV-2, spike protein, Receptor-binding domain, Coronavirus,
- 35 Serology, Humoral immune response, Neutralizing antibody, Isotypes

36 INTRODUCTION

37 Human pathogenic coronaviruses (CoV) such as severe acute respiratory syndrome (SARS)-38 CoV-1, middle east respiratory syndrome (MERS)-CoV, and SARS-CoV-2 (all β -CoVs) have 39 resulted from zoonoses and utilize cellular receptors to bind and access host cells for productive 40 infection (1-3). CoV spike (S) proteins are large (>200 kDa) glycosylated trimeric structures that 41 protrude from viral particles and enable binding of CoV to cellular receptors. SARS-CoV-2 42 interacts with angiotensin converting enzyme-2 (ACE2) via a flexible receptor-binding domain 43 (RBD) located on the distal tip of the S protein (4-7). After binding, several proteases act upon 44 S, priming it to adopt large conformational shifts that facilitate entry into host cells(8). First the 45 S1 domain (which contains RBD) is cleaved from the C-terminal S2 domain. For SARS-CoV-2 46 this process may involve furin in the host cell membrane due to a novel furin-recognition site in 47 the S1/S2 region (9-11). The S2 domain is further processed by other serine and cysteine-48 proteases such as trypsin, cathepsin, and TMPRSS2 to facilitate viral entry into the host cell (4, 49 12).

50 Neutralizing antibodies to SARS CoV-1 have been isolated and were found to target 51 RBD-S (13). One of these mAbs CR3022 was also found to bind SARS-CoV-2 RBD-S(14). At 52 the polyclonal level, the quantity of anti-RBD S IgG antibodies against SARS-CoV-2 correlate 53 well with neutralizing activity(15-18). Cross-neutralization amongst SARS viruses by RBD-S-54 targeting antibodies can occur (18-21). However, sequence homology for RBD-S is low for non-55 SARS β -CoVs (such as MERS) and for α -CoVs such as NL63, OC43, 229E, and HKU1(16, 17). 56 For these reasons serology for SARS-CoV-2 RBD-S is being used to help identify recovered 57 COVID-19 patients as plasma donors for passive immunotherapy (22).

58 There are several risk factors for COVID-19 mortality but whether two of these – age and 59 biological sex – are associated with the SARS-CoV-2 RBD-S immune response has to our 60 knowledge not been addressed in the peer-reviewed literature. Furthermore, most serology

- 61 studies have been done in the setting of severe COVID-19 disease and, save for one study
- 62 (17), without the benefit of detailed kinetics. Herein we tracked the kinetics and magnitude of
- 63 neutralizing and anti-SARS-CoV-2 S and RBD-S antibodies in a cross-sectional cohort of PCR-
- 64 confirmed COVID-19 patients.

66 RESULTS AND DISCUSSION

67 We chose a two-step ELISA-based RBD-S-focused approach to serology in our study 68 population. Reagents and pre-print protocols were available in mid-March 2020, which indicated 69 that RBD-S screening and full-S confirmation could identify specific and functional antibodies 70 and be quickly operationalized. Using the established protocol (23) we confirmed the expected 71 protein size of mammalian-expressed RBD-S (Figure 1A) and trimerized spike (Figure 1B) 72 produced from DNA plasmids (gift from Florian Krammer, Mt Sinai School of Medicine). RBD-S 73 antibodies were specific and correlated with neutralization (15), findings that have been 74 validated using similar RBD-S-focused assays(16, 17). We confirmed RBD-S and S protein 75 conformation by binding of CR3022 human lgG1 (Figure 1C, D). CR3022 was isolated as a 76 SARS-S1 domain-binding single chain antibody fragment by phage display and is neutralizing 77 as an IgG1(13). CR3022 binds adjacent to RBD-S in trimeric S of SARS-CoV-2 in a 78 glycosylation-sensitive manner(14). Mammalian expression of appropriate size proteins and 79 recognition by CR3022 together confirm that our protein preparations exhibited the expected 80 characteristics.

81 We first piloted our antigen preps for the RBD-S IgG screening assay using serum 82 samples from a PCR-confirmed severe COVID-19 patient (defined as admission to the Intensive 83 Care Unit, ICU) who was admitted to the hospital 10 days following symptom onset and based 84 on an early report suggesting that SARS-CoV-2 could trigger antibody responses in this 85 timeframe (24). We compared IgG reactivity in this sample to decreasing amounts of our RBD-S 86 antigen preparations against a fixed, recommended amount of commercially produced RBD-S 87 protein derived from the protocol we used (23). We found that a wide range of locally produced 88 RBD-S antigen yielded IgG reactivity equivalent to 100 ng of commercial antigen in an acute 89 serum sample from this COVID-19-positive patient (Figure 1E). No signal was observed in a 90 pre-2019 serum sample or in the absence of serum (Figure 1E). Using the standard 100 ng 91 amount hereafter, we found that RBD-S-binding IgM and IgG were present at 10-13 days after

92 symptom onset. We did not detect any RBD-S-binding in healthy pre-2019 sera (Figure 1F), in 93 agreement with extensive testing of this assay in pre-COVID-19 serum performed elsewhere 94 (15). Due to different secondary antibodies for IgM and IgG detection we cannot conclude 95 whether absolute levels of RBD-S IgG were higher than RBD-S IgM. Total IgG and IgM were 96 readily detected in both COVID-19 and in healthy non-COVID-19 serum (Figure 1G). 97 For a cross-sectional COVID-19 serological survey we collected serum samples from 32 98 patients that tested COVID-19 positive by nasopharyngeal swab RT-gPCR testing. All patients 99 had been admitted to the hospital and 13/32 (40%) were admitted to the ICU. Twenty-five 100 patients were subsequently discharged and 7 died. One to five serum samples were collected 101 from each patient with the first sample being taken within approximately 9 days after diagnosis. 102 in which diagnosis occurred around 5 days after symptom onset (**Table 1**). There was a 103 53%:47% male: female distribution and patients were on average 68 ± 14 years of age (range 104 30 -93 years) (Table 1).

105 A male bias in COVID-19 mortality was reported early during the pandemic (25-27) and 106 has been confirmed worldwide in a recent meta-analysis (28). One of the hypotheses to explain 107 this is differences in adaptive immunity between males and females. Although the mean serum 108 RBD-S IgG reactivity level appeared higher in male samples (O.D. = 1.8, n = 40) versus female 109 samples (O.D. = 1.0, n = 37) this difference was not significant and the same maximum 110 reactivity values were found in males and females (**Figure 2A**).

Although not absolute, it appears that irrespective of comorbidities, there is a higher risk of COVID-19 mortality and morbidity in older individuals (60 years of age and over) (29-31). We therefore assessed RBD-S IgG antibodies by age. There was a broad range of RBD-S IgG responses that did not differ as a function of age as assessed by correlation analysis ($R^2 < 0.01$, **Figure 2B**). Notably, one of the highest RBD-S IgG responses was from a 93-year old patient. A serum sample from a 30-year old COVID-19 patient was negative for RBD-S IgG, but this sample was taken just three days after symptom onset, which may be too early for induction of

robust IgG responses. Taken together, we did not find evidence of biological sex- or age-related
deficiencies in RBD-S IgG responses in COVID-19 patients.

120 RDB-S-reactive serum IgG was detected in 5 of 12 (42%) samples that were taken 121 within 10 days of symptom onset (Figure 2C). After day 10 of symptoms, 98% of samples were 122 positive for RBD IgG (Figure 2C). There were small variations in positive threshold for RBD by 123 assay date (Figure S1). We therefore confirmed each sample (whether RBD-positive or not) 124 with an endpoint titration and area under the curve calculation for reactivity against the full spike 125 ectodomain trimer (15). Samples that were RBD-S-negative were also low for spike total 126 reactivity (AUC) and titer (Figures 2D, E). Furthermore, we found a very strong correlation 127 between RBD and spike IgG (Figure 2F). The low level of spike reactivity in RBD-negative 128 samples could indicate a baseline cross-reactivity against other human coronaviruses (32). S 129 cross-reactivity would presumably occur in regions outside the RBD given the low conservation 130 of SARS-CoV-2 RBD compared to other human CoVs with the exception of SARS-CoV-1 (16). 131 Nonetheless, we found a strong correlation between RDB-S IgG and microneutralization titers 132 (Figure 2G), confirming the utility of RBD-S serology for estimation of functional neutralizing 133 antibodies in agreement with other studies (15-17).

134 In the patient-specific RBD IgG data (Figure S2A) we found several patterns: initial 135 seroconversion (e.g. patients 0003, and 0017), rapid increases (e.g. patients 0005, 0006, 0009, 136 0011, 0020, occurring between days 10-20), and plateaued responses (e.g. patients 0012 and 137 0021, occurring mainly after day 20). These responses were concordant with temporal patient-138 specific S IgG titers (Figure S2B). Anti-S titers in patients with a negative RBD-S test were 139 generally low and in RBD-positive samples, followed the same trends as RBD-reactivity, 140 providing further confirmation of robust serological responses to SARS-CoV-2 during acute 141 COVID-19. At the patient level, neutralizing activity was observed after as few as five days after 142 symptom onset and throughout the study period and was predominantly found in those samples 143 with positive RBD-S IgG (Figure S3).

144 To assess antibody isotype dynamics during acute SARS-CoV-2 we followed RBD-S 145 and full spike-specific IgM and IgA levels in the same samples for which RBD-S and spike IgG 146 was determined. At the patient level we found robust co-occurrence of IgM, IgG, and IgA 147 antibodies reactive to RBD-S in most samples, particularly in post-day 10 samples (Figure S4). 148 Pooling all the data revealed that all pre-day 10 RBD-S responses for all isotypes were low. 149 Around day 10, IgM targeting RBD-S as well as the switched isotypes IgG and IgA 150 simultaneously rose. While RBD-reactive IgM and IgA responses tapered after 3 weeks post-151 onset (though remained higher than baseline), those for IgG continued to rise to a plateau that 152 was sustained up to 5 weeks after symptoms onset (the most protracted timepoint measured, 153 Figure 3A). Similar patterns were obtained for full spike-reactive antibodies (Figure 3B). These 154 results suggesting that during acute infection COVID-19 patients undergo a seroconversion 155 across isotypes to SARS-CoV-2 rather than an expansion of pre-existing anti-CoV antibodies. 156 Lastly, we assessed anti-RBD-IgG responses by clinical severity. All the patients in this 157 study were hospitalized and 40% of were admitted to the intensive care unit. When we stratified 158 by ICU admission and compared RBS-S IgG levels, we found a trend towards higher levels in 159 those requiring ICU-level care (P = 0.09) (Figure 4A). Additionally, we observed a significant association between RBD-S IgG and duration of ICU admission (Figure 4B). Lastly 7 of 32 160 161 (22%) patients succumbed to COVID-19. While a significant difference in the median RBD-S 162 IgG was not observed between survivors and decedents, a smaller range trending towards 163 higher RBD-S reactivity was observed in those patients that died (Figure 4C). Although we did 164 not have continuous monitoring of viral load in these patients during hospitalizations it is 165 possible that RBD-S IgG levels reflect ongoing viral replication during more severe disease and 166 in conjunction with other factors may allow for recovery. 167 Taken together, our results provide the first comprehensive survey of SARS-CoV-2 spike 168 RBD antibodies that accounts for two key risk factors for COVID-19. Neither RBD-S nor S

169 antibodies were significantly different as a function of biological sex. Anti-RBD-S and spike IgG

170 responses were induced across 6 decades of age with robust responses found in several samples from patients ≥ 80 years old. These results also extend kinetic analyses and confirm 171 172 the paucity of anti-SARS-CoV-2 anti-spike responses in very early blood samples taken prior to 173 day 10 after symptoms onset (17, 24). We also assessed protective anti-spike RBD responses 174 as a function of level of hospital care and disease severity and found that duration of ICU-level 175 care was associated with higher responses, possibly due to an extended period of SARS-CoV-2 176 replication during severe disease. A limitation of our study is that we only followed symptomatic 177 patients admitted to hospital: it is unclear whether antibody responses differ in asymptomatic or 178 mildly symptomatic patients. We also did not directly assess whether the RBD-specific 179 antibodies we studied were neutralizing at the clonal level, though we did observe a strong 180 association with polyclonal RBD-S IgG responses and SARS-CoV-2 neutralizing activity. This is 181 in agreement with other reports which confirm that RBD-S IgG levels correlate with neutralizing 182 activity and that the RBD of SARS-CoV-2 is a potent target for neutralizing antibodies (16-18, 183 20, 21, 33). It will be important to determine whether anti-RBD IgA or even IgM antibodies 184 contribute to blocking activity.

185 Methods.

186 COVID-19 samples.

187 Patients were admitted to the University of Vermont Medical Center (UVMMC), situated 188 in a low-density (26-112 persons/km²) catchment area with a COVID-19 diagnosis from a PCR-189 positive swab testing performed within a CLIA-certified clinical laboratory. University of Vermont 190 Institutional Review Board approval was granted under registration STUDY00881. Samples and 191 patient data were obtained under Exemption 4, Waiver of Consent and UVM/UVMMC HIPAA 192 Authorization under 46.116(f)(1)(3), 46.164.512(i)(1)(2). Patient IDs are coded here as 193 "CDDx.001-032". Deidentified patient (age, sex) and clinical data (COVID-19 diagnosis, dates of 194 symptom onset, hospitalization, intensive care unit admission) were obtained from the electronic 195 health record.

196 **RBD-S and spike antigen preparations.**

197 pCAGGS plasmids containing hexahistidine-tagged SARS-CoV-2 spike glycoprotein receptor

binding domain (RBD-S) and trimerized SARS-CoV-2 (15, 23) were obtained as Whatman spots

199 from Florian Krammer (Mt. Sinai School of Medicine), and transformed into *E.coli* to make

200 plasmid stocks. We sequence verified these using pcaggs-F (5'-GTTCGGCTTCTGGCGTGT-3')

201 and pcaggs-R (5'-TATGTCCTTCCGAGTGAGAG-3'). Plasmids were then transfected into

202 Expi293F cells (Gibco #A14527) and protein was purified by Ni-NTA agarose resin (Qiagen

203 #30230) as described (23). Protein was quantified using bovine serum albumin as a standard

204 (Sigma A4505, Cohn Faction V) and Bradford reagent (Bio-Rad, 5000006). Protein was run on

denaturing 4–20% recast protein gels (Bio-Rad 4561094) and visualized by Coomassie blue

staining with a 10-190 kDa protein ladder (Invitrogen 10748-010).

Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-CoV-2, Wuhan-Hu-1,
was also used as a positive control during assay set up and this reagent was produced in
HEK293T cells under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH:

210 Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2,

- 211 Wuhan-Hu-1, Recombinant from NR-52306.
- 212 **Preparation of CR3022 monoclonal antibody.**

213 CR3022 is a SARS-CoV S-specific antibody originally isolated by single chain variable region 214 phage display and then cloned as an IgG1/kappa monoclonal human IgG1/ κ (13). We received 215 CR3022 heavy chain (HC) and light chain (LC) cloned into pFUSEss-CHIg-hG1 and pFUSE2ss-216 CLIg-hK, respectively (Invivogen) from Florian Krammer spotted on filter paper. We 217 resuspended spots in 100 µL TE and transformed 20 µL E. coli (NEB C2987H) with 1 µL 218 followed by growth in the presence of Zeocin (25 µg/mL, Invivogen, for CR3022-HC) and 219 blasticidin (100 µg/mL, Invivogen for CR3022 LC). Midi-preps were then sequenced confirmed 220 CR3022HC (Genbank DQ168569) and LC (Genbank DQ168570) with primer HTLV-5'UTR 221 (forward) 5'-GCTTGCTCAACTCTACGTC-3' and CR3022-HC in the reverse direction by primer 222 Fc (reverse): 5'CTCACGTCCACCACCACGCA-3'. Recombinant CR3022 was expressed in 223 293A cells (Invitrogen) by polyethyleneimine (Polysciences Inc.) transfection of 9 µg each of 224 CR3022-HC and LC, culture for 7 days, and protein A agarose bead purification as described 225 (34). IgG was guantified by sandwich ELISA with anti-human IgG (Jackson Immunoresearch 226 109-005-008) as capture and horseradish peroxidase-conjugated anti-human IgG (Jackson

- Immunoresearch, 109-005-008) as detection Ab with known human serum as a standard.
- 228 Clinical RBD-S and S IgG ELISA testing

For IgG against RBD-S from SARS-CoV-2 we followed Stadlbauer et al (23) and the Emergency

Use Authorization granted to MSSM by the Food and Drug Administration on 4/15/2020

231 (https://www.fda.gov/media/137029/download). Briefly, for RBD-S IgG levels 96-well plates

- were coated with 100 ng/well of purified RBD-S and then blocked with 3% milk in phosphate-
- buffered saline (PBS) containing 0.1% Tween-20 (T). Heat-inactivated (56°C for 1 hr) serum
- samples were diluted 1:5 in PBS, and 20 µL of this was added to 180 µL of dilution buffer (PBS-

235 T + 1% milk) in each well for 1:50 final dilution of sample. 100 µL of sample is then added to 236 each well and after 1 hr incubation at room temperature and washing with PBS-T using a Biotek 237 ELx-405 Select CW (Biotek, Winooski, VT), IqG was detected with alkaline phosphatase-238 conjugated cross-adsorbed anti-human IgG (Sigma SAB3701277, diluted 1:2,500 in blocking 239 buffer), washing, and addition of p-nitrophenylphosphate (Sigma N2770) substrate. The 240 colorimetric reaction (optical density at 405 nm) was detected with a Cytation 3 (Biotek, 241 Winooski, VT). Two negative control samples of pre-2019 serum were used on each plate and 242 the average + three standard deviations above the mean were used as the assay cutoff for 243 positivity. 244 For S detection heat-inactivated serum samples were diluted 1:5 in PBS and then 20 µL

245 was added to 180 μ L of dilution buffer in the starting well (for a final 1:100 starting dilution) then

serially diluted 1:3 to an endpoint dilution of 1:8,100. IgG detection was performed as described

above with 100 μL of 1:100 sample. Endpoint titer was defined as the last dilution at which the

signal was above the cutoff (defined as was done for RBD-S above). spike area under the curve

249 (AUC) was calculated in Prism 8.4.3 (Graphpad Inc) from the OD_{405nm} values from all six

250 dilutions and using the negative control cutoff values as the baseline.

251 Testing for RBD-S and S IgM and IgA in clinical samples by ELISA

252 Samples were handled as above for IgG except that the detection steps used alkaline

253 phosphatase-conjugated anti-human IgM (Sigma A3437, diluted 1:1,000 in blocking buffer) or

254 IgA (Sigma A3400, diluted 1:1,000 in blocking buffer).

255 SARS-CoV-2 microneutralization assay

All experiments featuring infectious SARS-CoV-2 were conducted at the UVM BSL-3 facility

257 under an approved Institutional Biosafety protocol. SARS-CoV-2 strain 2019-nCoV/USA_USA-

258 WA1/2020 (WA1) was generously provided by Kenneth Plante and the World Reference Center

- for Emerging Viruses and Arboviruses (WRCEVA) at the University of Texas Medical Branch
- and propagated in African green monkey kidney cells (Vero E6) that were kindly provided by J.L

261 Whitton, Vero E6 cells were maintained in complete Dulbecco's Modified Eagle Medium (cDMEM) (11965–092) containing 10% fetal bovine serum (FBS) (16140–071), 1% HEPES 262 263 Buffer Solution (15630–130), and 1% penicillin-streptomycin (15140–122) purchased from 264 Thermo Fisher Scientific (Carlsbad, CA). Cells were grown in a humidified incubator at 37°C 265 with 5% CO₂. To assess the neutralization capacity of patient sera against authentic SARS-266 CoV-2, we conducted a focus reduction neutralization test (FRNT). Each serum sample was 267 heat inactivated via incubation at 56 °C for 1 h. Samples were then diluted serially in 25 µL of 268 cDMEM, mixed with an equal volume of cDMEM containing 175 focus forming units (FFU) of 269 SARS-CoV-2, and then incubated for 60 minutes at 37°C. Each serum sample was tested for 270 neutralization at an initial dilution of 1:50 and then serially at 1:2 dilutions until reaching an 271 endpoint of 1:3,200. The media from confluent Vero E6 cell monolayers in 96-well white 272 polystyrene microplates (07-200-628, Thermo Fisher Scientific) was removed and 50 µL of each 273 antibody-virus mixture was inoculated onto the cells and incubated at 37°C in a 5% CO₂ 274 incubator for 60 minutes, after which the wells were overlaid with 1.2% methylcellulose in 275 cDMEM and incubated at 37°C in a 5% CO₂ incubator for 24 h. Infected cells were fixed in 25% 276 formaldehyde in 3X phosphate buffered saline (PBS). Cells were permeabilized with 0.1% 100X 277 Triton in 1X PBS for 15 minutes and then incubated with a primary, cross-reactive rabbit anti-278 SARS-CoV N monoclonal antibody (40143-R001, Sinobiological) (1:20,000) followed by a 279 peroxidase-labeled goat anti-rabbit antibody (5220-0336, SeraCare) (1:2,000) and then the 280 peroxidase substrate (5510-0030, SeraCare). Images of the wells were captured using a Zeiss 281 AxioCam MRC Imager.M1 microscope and viral foci were quantified manually. Focus counts 282 were normalized to virus only control wells. FRNT₅₀ determinations were made using a non-283 linear regression curve fit (log[inhibitor] vs. normalized response – variable slope) in GraphPad 284 Prism.

285 **Graphics and Statistical testing**.

- All statistics and graphics were performed using R version 3.6.1 using standard packages or
- 287 GraphPad Prism 8.4.3. Non-parametric LOESS (LOcal regrESSion) was used for smoothing.

288 Acknowledgements

- We thank all health care workers and laboratory personnel who contributed to treatment and diagnosis of these and other COVID-19 patients. We thank the clinical research staff at the University of Vermont (UVM) Medical Center Pathology and Laboratory Medicine and the Vaccine Testing Center. We also thank the UVM Research Protections Office, Institutional Review Board, and Institutional Biosafety Committee for rapid turnaround of COVID-19-related projects. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- 296 Funding
- 297 This work was funded by a pilot grant to SAD and EB from the UVM Translational Global
- 298 Infectious Disease Research Center (National Institute of Health grant P20GM125498).
- Additional funding was from NIH grant U01AI141997 to SAD, JWB, and BDK, the Office of the
- 300 Vice President for Research at the University of Vermont to JWB, and the University of Vermont
- 301 Larner College of Medicine Department of Surgery. Sequencing confirmation of reagents was
- 302 performed in the Vermont Integrative Genomics Resource Sequencing Facility and was
- 303 supported by the UVM Cancer Center, Lake Champlain Cancer Research Organization, UVM
- 304 College of Agriculture and Life Sciences, and the UVM Larner College of Medicine.

305 Author contributions:

- 306 SAD, JWC, and JWB conceived and designed the project. NRG, ANW, CAS, BDM, and SAD
- 307 performed experiments. AKM, DG, and JWC provided samples. EAB, JWB, MEP, KKP, BDK,
- 308 RDS, GA, and SAD provided resources and/or key project input. SAD wrote the manuscript with
- input from all authors. Supervision: SAD, JWC, and JWB.
- 310 **Declaration of interests:** The authors declare no competing interests.

311 **REFERENCES**

- Cui J, Li F, and Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol.* 2019;17(3):181-92.
- Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet.* 2020;395(10224):565-74.
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
 associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-3.
- Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al.
 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
 Proven Protease Inhibitor. *Cell.* 2020;181(2):271-80 e8.
- Wan Y, Shang J, Graham R, Baric RS, and Li F. Receptor Recognition by the Novel
 Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of
 SARS Coronavirus. *J Virol.* 2020;94(7).
- Watanabe Y, Allen JD, Wrapp D, McLellan JS, and Crispin M. Site-specific glycan
 analysis of the SARS-CoV-2 spike. *Science*. 2020;91:eabb9983-9.
- Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*.
 2020;367(6483):1260-3.
- B. Hulswit RJ, de Haan CA, and Bosch BJ. Coronavirus Spike Protein and Tropism
 Changes. *Adv Virus Res.* 2016;96:29-57.
- Hoffmann M, Kleine-Weber H, and Pohlmann S. A Multibasic Cleavage Site in the Spike
 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell.* 2020;78(4):779-84 e5.
- Jaimes JA, Andre NM, Chappie JS, Millet JK, and Whittaker GR. Phylogenetic Analysis
 and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct
 and Proteolytically Sensitive Activation Loop. *J Mol Biol.* 2020;432(10):3309-25.
- Jaimes JA, Millet JK, and Whittaker GR. Proteolytic Cleavage of the SARS-CoV-2 Spike
 Protein and the Role of the Novel S1/S2 Site. *iScience*. 2020;23(6):101212.
- 340 12. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of
 341 SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat* 342 *Commun.* 2020;11(1):1620.
- ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, et al. Human
 monoclonal antibody combination against SARS coronavirus: synergy and coverage of
 escape mutants. *PLoS Med.* 2006;3(7):e237.

- Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, et al. A highly conserved cryptic epitope
 in the receptor binding domains of SARS-CoV-2 and SARS-CoV. *Science*.
 2020;368(6491):630-3.
- Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al.
 A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med.*2020;5:562-12.
- 352 16. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al.
 353 The receptor binding domain of the viral spike protein is an immunodominant and highly
 354 specific target of antibodies in SARS-CoV-2 patients. *Sci Immunol.* 2020;5(48).
- 355 17. Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et
 356 al. Rapid generation of neutralizing antibody responses in COVID-19 patients. *Cell*357 *Reports Medicine*. 2020.
- 358 18. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited
 359 by SARS-CoV-2 infection. *Nature*. 2020.
- Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, and Veesler D. Structure,
 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell.*2020;181(2):281-92 e6.
- Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Crossneutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature*.
 2020.
- Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, et al. Broad
 neutralization of SARS-related viruses by human monoclonal antibodies. *Science.* 2020.
- Liu STH, Lin H-M, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent
 plasma treatment of severe COVID-19: A matched control study. *medRxiv*.
 2020:2020.05.20.20102236.
- Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al.
 SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay,
 Antigen Production, and Test Setup. *Curr Protoc Microbiol.* 2020;57(1):e100.
- To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of
 viral load in posterior oropharyngeal saliva samples and serum antibody responses
 during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis.*2020;20(5):565-74.
- Wu Z, and McGoogan JM. Characteristics of and Important Lessons From the
 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*.
 2020.
- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
 descriptive study. *Lancet.* 2020;395(10223):507-13.

- 385 27. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
 386 Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382(18):1708-20.
- Scully EP, Haverfield J, Ursin RL, Tannenbaum C, and Klein SL. Considering how
 biological sex impacts immune responses and COVID-19 outcomes. *Nat Rev Immunol.*2020.
- Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the
 severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis.*2020;20(6):669-77.
- 30. laccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe M, et al. Age and
 Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS
 Study of the Italian Society of Hypertension. *Hypertension*.
 2020:HYPERTENSIONAHA12015324.
- 397 31. Miller IF, Becker AD, Grenfell BT, and Metcalf CJE. Disease and healthcare burden of
 398 COVID-19 in the United States. *Nat Med.* 2020.
- 399 32. Meyer B, Drosten C, and Muller MA. Serological assays for emerging coronaviruses:
 400 challenges and pitfalls. *Virus Res.* 2014;194:175-83.
- Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and Functional Basis
 of SARS-CoV-2 Entry by Using Human ACE2. *Cell.* 2020;181(4):894-904 e9.
- 403 34. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, et al. Rapid
 404 generation of fully human monoclonal antibodies specific to a vaccinating antigen. *Nat*405 *Protoc.* 2009;4(3):372-84.
- 35. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, and Crowe JE, Jr. Isolation of
 dengue virus-specific memory B cells with live virus antigen from human subjects
 following natural infection reveals the presence of diverse novel functional groups of
 antibody clones. *J Virol.* 2014;88(21):12233-41.

410

412 Tables

413 Table 1

COVID-19 subjects	Male/ Female	AGE ± S.D. [Range]	Days from symptoms to Dx	Days between Dx and 1 st serum
Swab PCR+ (n = 32)	17/15	68 ± 14 [30-93]	5.4 ± 4.7 [0-14]	8.6 ± 7.5 [0-35]

415 Figures





- 418 Reducing SDS-PAGE analysis of (A) RBD-S and (B) trimeric spike purified from transiently
- 419 transfected mammalian HEK293 cells. (C) Binding of CR3022 IgG1 mAb to SARS-CoV-2 RBD-
- 420 S and (**D**) trimerized spike. The anti-dengue virus 1M7 mAb (35) was used as a control (**E**)
- 421 Detection of serum IgG from a COVID-19 patient (left), but not from pre-2020 serum (center) or

- 422 no serum control (right). (F) Detection of IgM and IgG to RBD-S in serial serum samples from
- 423 COVID-19 patient and not in pre-2020 healthy volunteer sera (all sera diluted 1:50 and for
- 424 COVID-19 patient, day after onset is shown in label). (G) Total IgM and IgG reactivity in a 1:50
- 425 dilution of serum from panel F.





- 433 (1:100 1:8,100) and plotted against days of symptoms. (E) Spike IgG endpoint titer or (F) AUC
- 434 is plotted against RBD-IgG reactivity. (G) SARS-CoV-2 microneutralization titers are plotted
- 435 against RBD-S IgG reactivity. Cutoff values (dashed line) are shown. Spearman's Rho
- 436 coefficient (R^2), 95% confidence interval (shading), and *P*-value are shown for B-G.





439 (A) RBD-S IgM, IgG, and IgA in serum (diluted 1:50) were determined by ELISA and plotted

440 against days post onset of symptoms. LOESS-smoothed lines and 95% confidence intervals are

shown for each isotype. (B) (A) Spike-reactive IgM, IgG, and IgA in serum (diluted 1:100) were

- determined by ELISA and plotted against days post onset of symptoms. LOESS-smoothed lines
- 443 and 95% confidence intervals are shown for each isotype.



Figure 4 | SARS-CoV-2 RBD-S lgG responses during hospitalization. (A) RBD-S lgG in
patients that were hospitalized in the ICU or not were analyzed by student's t-test and *P*-value is
shown. Boxplots show the median, 95% confidence level and all individual samples. (B) For ICU
hospitalized patients, all RBD-S lgG values are presented as a function of ICU admission days.
Spearman's Rho coefficient (*R*²), 95% confidence interval, and *P*-value are shown. (C) RBD-S
lgG in patients that were deceased or discharged were analyzed by student's t-test and *P*-value
is shown. Boxplots show the median, 95% confidence level, and all individual samples.